Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
VUF10460
Cat. No.:
OB0225LY-0156
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
VUF10460 is a novel drug candidate that acts primarily as a modulator of specific neural pathways.
Synonym:
1028327-66-3; VUF 10460; VUF10460; 4-(4-Methylpiperazin-1-yl)-6-phenylpyrimidin-2-amine; 4-(4-Methyl-1-piperazinyl)-6-phenyl-2-pyrimidinamine; 4-(4-Methyl-piperazin-1-yl)-6-phenyl-pyrimidin-2-ylamine
CAS No.:
1028327-66-3
Compound CID:
25129523
Formula:
C15H19N5
Formula Weight:
269.34
Specification
Relative Density:
1.187 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
VUF10460 can be used in neuroscience research or play an important role in drug discovery to explore its potential therapeutic role.
Library Information
Targets:
Histamine receptor
Receptors:
H4 receptor
Pathways:
Neuronal signaling; GPCR/G protein; Immunology/Inflammation
Plate Number:
AOCL-2
Plate Location:
h9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
45 mg/mL; 167.07 mM
